Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications Authors: Liming Zhu, Jiayao Xu, Dong Niu, Xiangyu Zhang, Chunhui Jin Published: 2026 ABSTRACT ABSTRACTThe gut microbiome has emerged as a pivotal regulator of immunotherapy efficacy in non‐small cell lung cancer (NSCLC), with mounting evidence demonstrating that microbial‐immune crosstalk significantly influences therapeutic responses. Current research reveals that commensal bacteria modulate host immunity through complex metabolic and immunological pathways, yet the precise mechanisms underlying these interactions remain incompletely characterized. Meanwhile, the substantial heterogeneity of microbial ecosystems across individuals and the lack of standardized protocols for microbiota‐based therapeutic interventions pose significant barriers to clinical translation. Furthermore, unresolved questions persist regarding the safety profiles and reproducibility of clinical outcomes associated with microbial modulation. Addressing these knowledge gaps could provide transformative insights into immunotherapy resistance while enabling the development of precision medicine approaches. This narrative review synthesizes current knowledge on the clinical impact of gut microbiota on the immunotherapy response in NSCLC, mechanistic insights into the interactions between gut microbiota and the lung cancer immune microenvironment, and the challenges in clinical translation. By integrating these perspectives, we develop a practical framework for implementing microbiota‐based strategies to enhance immunotherapy efficacy, with the hope of addressing current limitations in biomarker development, intervention protocols, and personalized treatment approaches to bridge the gap between research and clinical practice in precision oncology.Keywords: gut microbiota, gut‐lung axis, immunotherapy, metabolomics, NSCLC Introduction Immune checkpoint inhibitors (ICIs) have emerged as a pivotal approach in the treatment of advanced NSCLC lacking driver mutations, being utilized in first‐line therapies, subsequent treatment regimens, consolidation therapy following concurrent chemoradiotherapy in locally advanced cases, and as postoperative adjuvant therapy for resectable patients. Clinical investigations have demonstrated that patients exhibiting high levels of programmed death‐ligand 1 (PD‐L1) expression (≥ 50%) can attain a median overall survival (OS) of 26.3 months with monotherapy, which is significantly superior to outcomes observed with chemotherapy [1]. However, existing evidence indicates that this treatment strategy still faces key bottlenecks. Firstly, the objective response rate remains low. Only 15%–30% of NSCLC patients show a durable response to monotherapy [2], with resistance mechanisms potentially related to immune microenvironment suppression [3, 4, 5, 6, 7], T cell exhaustion [8, 9], and tumor metabolic reprogramming [10]. Secondly, immune‐related adverse events (irAEs) are significant, with the incidence of grade 3–4 pneumonia and colitis reaching as high as 67.2% [11, 12]. Moreover, existing biomarker frameworks exhibit notable limitations, including inconsistent detection protocols for tumor mutation burden (TMB), spatiotemporal heterogeneity in PD‐L1 expression across tumors, and the impact of prior treatments, such as chemotherapy, which can enhance PD‐L1 expression [2, 13]. It is worth noting that more and more evidence suggests that the intestinal microbiome may become a new target for improving tumor immunotherapy. The intestinal microbiome is mainly composed of three major categories: bacteria, fungi and viruses. Bacteria, including Bacteroides and Firmicobacteria, account for more than 90% of the microbiota and have been shown to regulate host immunity by metabolic by‐products such as short‐chain fatty acids (SCFAs). Fungi such as Candida and Saccharomyces account for approximately 0.1% of the microbiota and interact with the host's immune system through pattern recognition receptors such as Dectin‐1, thereby contributing to anti‐tumor immune regulation. Viruses (e.g., bacteriophages) indirectly affect the host's immune homeostasis by regulating the number of bacteria [14, 15]. The intestinal microbiota affects the efficacy of immunotherapy and patient prognosis by affecting the host's immune response. Therefore, given that the intestinal microbiota has multiple regulatory effects on the host's immune system, targeted intervention on the regulation of the intestinal microbiota may help improve the effectiveness of immunotherapy for NSCLC and may open up a way to improve patient clinical outcomes. This article will meticulously analyze the latest developments in the strategic adjustment of gut microbiomes in conjunction with NSCLC immunotherapy. It delves into the intricate processes by which the gut's microbial community influences the body's immune response to tumors, while assessing the existing hurdles in research and outlining what lies ahead. Its aim is to provide a robust theoretical base and practical guidelines that enhance the accuracy and customization of NSCLC treatments. Characteristics of Gut Microbiota in NSCLC Patients Changes in Gut Microbiota Diversity and Structure Human Gut Microbiota Diversity refers to the richness and evenness of species types, quantities, and functional distribution within the microbial communities in the human intestine [16]. This diversity is typically reflected in species richness, functional diversity, ecological balance, and dysbiosis [17, 18, 19]. Among these, α‐diversity and β‐diversity can illustrate species richness and evenness. α‐diversity is used to measure the richness and evenness of microorganisms within a single sample [20], with commonly used α‐diversity indices including the Chao1 index, ACE index, Shannon index, Simpson index, etc. [21]. α‐diversity serves as an important indicator of the ecological state of the microbial community within an individual sample. β‐diversity is employed to compare overall differences in microbial community composition between different samples or groups, effectively revealing structural changes in the microbiota caused by disease, intervention, or environmental factors [20]. Diet and disease can both alter the diversity of gut microbiota and even lead to dysbiosis [22, 23, 24]. For instance, in rheumatic diseases, a significant decrease in α‐diversity of gut microbiota is observed [25]. The gut microbiota diversity in patients with Alzheimer's disease and Parkinson's disease shows significant differences compared to healthy individuals, and probiotics or antibiotics may prevent or improve neuropsychiatric symptoms in Alzheimer's disease and Parkinson's disease [26]. Patients diagnosed with NSCLC exhibit a notable decline in gut microbiota diversity, as indicated by the Shannon index, alongside a decrease in microbial richness. The occurrence is marked by a decline in advantageous microbial communities along with a rise in potentially harmful microorganisms. With disease progression, both α‐diversity (measured using the Chao1 and Observed Species indices) and β‐diversity diminish further when compared to healthy subjects, leading to a considerably less diverse and less abundant gut microbiota particularly evident at the metastatic stage [27]. Altered microbiome composition is characterized by a decline in advantageous bacteria and a rise in detrimental ones, such as certain SCFA‐producing bacteria (e.g., Prevotella, Faecalibacterium, Bifidobacterium, Butyricicoccus, Akkermansia muciniphila , Coprococcus, Ruminococcus, Eubacterium hallii , and Roseburia intestinalis ), which significantly decrease, impairing SCFA metabolism and secondary bile acid metabolic functions [27, 28]. Pathogenic bacteria (e.g., Fusobacteria, Proteobacteria, Enterococcus, Eggerthella lenta , Clostridium innocuum ) are enriched in NSCLC patients, particularly at the metastatic stage [29]. Differences in Microbiota Across Disease Stages The gut microbiota composition in early NSCLC patients is similar to that of healthy individuals, but specific bacterial genera show changes in abundance [30]. Studies indicate that as NSCLC progresses, from atypical adenomatous hyperplasia/adenocarcinoma in situ (AAH/AIS) to invasive adenocarcinoma (IA), microbiota diversity gradually decreases, with the Shannon index significantly declining, 32% lower in IA than in AAH/AIS, and the Chao1 index decreasing by 41%, with serum metabolite levels dropping by 28%. Protective microbiota (e.g., Faecalibacterium, Roseburia) decrease by 4–8 times in IA, while pro‐inflammatory microbiota (e.g., Escherichia, Shigella) increase by 6.5 times in IA [30, 31]. Furthermore, the relative abundance of Bacteroides and Prevotella is significantly reduced. Bacteroides plays a crucial role in bile acid metabolism, stimulating dendritic cell (DC) activation and promoting CD8+ T cell‐mediated immunity. Meanwhile, Prevotella modulates the equilibrium between regulatory T cells (Tregs) and T helper 17 (Th17) cells via the Tryptophan‐Kynurenine‐Aryl Hydrocarbon Receptor (Trp‐Kyn‐AhR) signaling cascade. The decline in these microbial populations contributes to localized immunosuppression, ultimately fostering resistance to immunotherapy [32, 33, 34]. Patients diagnosed with advanced NSCLC demonstrate pronounced alterations in gut microbial composition. Notably, pro‐inflammatory bacterial taxa, including Proteobacteria and Enterobacteriaceae, exhibit marked enrichment, whereas beneficial commensals involved in SCFA production—such as Firmicutes and Lachnospiraceae—are substantially diminished [30, 31]. Concurrently, the Firmicutes‐to‐Bacteroidetes (F/B) ratio undergoes a significant elevation, coinciding with fungal overgrowth (e.g., Candida spp.), suggesting that microbial imbalance amplifies systemic inflammation [15]. Furthermore, tumor progression and metastatic dissemination correlate with increased abundance of NSCLC‐associated gut microbes, including Flavonifractor plautii , Eggerthella lenta , Clostridium innocuum , and Clostridium aldenense [28]. Preclinical studies corroborate these findings, revealing a similarly elevated F/B ratio in murine models of NSCLC brain metastasis [35]. Mendelian randomization analyses further support a causal relationship, demonstrating that heightened Ruminococcus levels elevate the risk of lung squamous cell carcinoma (LSCC) metastasis by 28% [36] (Table 1). TABLE 1Characteristics of intestinal flora in NSCLC patients.CategorizationChanges in flora diversityChanges in key floraRelated metabolic pathwaysClinical significanceBibliographyEarly stage (I–II)Decreased alpha diversity (Chao, Shannon, and Sobs decreased Shannon index increased), Decreased F/B ratio Enriched bacteria: Enterobacteriaceae Klebsiella Escherichia Lactobacillus Aminoacyl‐tRNA biosynthesis pathway, amino acid metabolism(L‐lysine, L‐isoleucine, and L‐histidine), Short‐chain fatty acid (butyric acid) metabolism Can be used as a secondary marker for early screening (combined with imaging)[30, 31, 32, 33, 34] Reduced bacterium: Faecalibacterium Prevotella Roseburia Middle to late stage (III–IV)Decreased alpha diversity, Decreased F/B ratio Enriched bacteria: Eggerthella lenta Flavonifractor plautii Clostridium aldenense Clostridium innocuum Leptotrichia Fusobacterium Streptococcus Enterococcus Ruminococcus Short‐chain fatty acid metabolism (butyrate, isovalerate, acetate, propionate), amino acid metabolism (Leucine degradation, propionyl coenzyme A catabolism, tryptophan), Secondary bile acid metabolism(fatty acid biosynthesis), Secondary bile acid metabolism, Fatty acid biosynthesisPredicting survival and immunosuppressant efficacy[27, 28, 31, 35, 36] Reduced bacterium: Firmicutes Oscillospiraceae Akkermansia Parabacteroides Roseburia Acutalibacteraceae Alistipes Characteristics of intestinal flora in NSCLC patients. Enriched bacteria: Enterobacteriaceae Klebsiella Escherichia Lactobacillus Aminoacyl‐tRNA biosynthesis pathway, amino acid metabolism(L‐lysine, L‐isoleucine, and L‐histidine), Short‐chain fatty acid (butyric acid) metabolism Reduced bacterium: Faecalibacterium Prevotella Roseburia Enriched bacteria: Eggerthella lenta Flavonifractor plautii Clostridium aldenense Clostridium innocuum Leptotrichia Fusobacterium Streptococcus Enterococcus Ruminococcus Reduced bacterium: Firmicutes Oscillospiraceae Akkermansia Parabacteroides Roseburia Acutalibacteraceae Alistipes Immunomodulatory Pathways Linking Gut Microbiota to NSCLC Microenvironment Modulation of the Immune‐Gut‐Lung Axis The gut microbiota is central to the “immune‐gut‐microbiota‐metabolism axis,” influencing the NSCLC tumor immune microenvironment via bidirectional gut‐lung crosstalk that mechanistically links intestinal microbial communities to pulmonary pathophysiology. This axis operates through three principal mechanisms: systemic circulation of microbial‐derived metabolites [37, 38], immune cell migration between gut‐associated lymphoid tissue (GALT) and mucosa‐associated lymphoid tissue (MALT) [39, 40], and neuroendocrine‐mediated communication along the gut‐brain‐lung triad [41, 42]. Dysregulation of this axis is strongly associated with immune checkpoint inhibitor (ICI) resistance and irAEs in NSCLC patients. Emerging microbial modulation strategies—including fecal microbiota transplantation (FMT), precision probiotics/prebiotics, and dietary interventions—show promise in rebalancing gut‐lung axis homeostasis. Such approaches may serve as innovative adjuncts to ICIs, potentially reversing resistance and improving outcomes, thereby advancing precision immunotherapy for NSCLC [43, 44] (Figure 1). Immune‐gut microbiota‐metabolic axis. This schematic shows the immune‐gut microbiota‐metabolic axis, highlighting how gut microbiota dysregulation, lung immune response, and metabolic changes interact. Key elements include gut microbiota metabolites affecting lung immunity, lung immune cells influencing intestinal barrier and microbiota balance, and immune cell migration between gut and lungs, illustrating the interplay of microbial ecology, immune homeostasis, and metabolism in NSCLC cancer. Metabolomics Analysis of Gut Microbiota in Regulating the Immune Microenvironment Metabolomics has emerged as an indispensable approach for deciphering the mechanistic links between gut microbiota and pulmonary immune modulation in lung cancer. Metabolomics has revealed that changes in the abundance of specific bacterial communities in the gut of NSCLC patients lead to alterations in their metabolic products, thereby affecting the efficacy of immunotherapy. A Mendelian randomization analysis has demonstrated a causal association between specific intestinal microbial communities and NSCLC development, with SCFA and bile acid metabolic pathways identified as key mediators. This investigation identified statistically significant interactions involving 13 distinct gut microbial taxa and 15 circulating metabolites, including:SCFAs (e.g., butyric acid, propionic acid), amino acids (e.g., tryptophan, tyrosine, branched‐chain amino acids), and secondary bile acids (e.g., deoxycholic acid) [45]. Following systemic absorption, these microbially derived metabolites are transported hematogenously to pulmonary tissues, where they exert substantial immunomodulatory effects on the tumor microenvironment [46]. In terms of SCFA metabolism, a decrease in SCFA‐producing bacteria within the intestines of NSCLC patients results in markedly lower SCFA levels (e.g., butyrate and propionate), which disrupt immune homeostasis through dual mechanisms: G protein‐coupled receptor (GPR43/GPR109A) activation and histone deacetylase (HDAC) inhibition. These changes promote regulatory T cell (Treg) differentiation while suppressing T helper 17 (Th17) cell activity, resulting in an imbalanced Th17/Treg ratio that facilitates tumor immune evasion. Furthermore, SCFA deficiency impairs dendritic cell function and reduces CD8+ T cell cytotoxicity, contributing to diminished responses to ICIs [14, 43, 47, 48, 49, 50, 51, 52]. At the metabolic level, insufficient SCFAs compromise intestinal barrier integrity by depriving colonocytes of their primary energy source, leading to bacterial translocation and systemic inflammation that may exacerbate NSCLC progression [30, 31]. Conversely, the enrichment of certain SCFA‐producing bacteria (such as Akkermansia muciniphila and Eubacterium hallii ) leads to elevated levels of butyrate in feces, which is positively correlated with CD8+ T‐cell infiltration within tumors. Furthermore, the accumulation of butyrate suppresses regulatory T cells and induces effector T cells. Consequently, the administration of SCFA‐producing probiotics via oral supplementation or fecal transplantation can enhance anti‐tumor immune responses [53, 54, 55]. Regarding amino acid (AA) metabolism, dysbiosis is often associated with considerable metabolic disturbances, particularly in branched‐chain amino acid (BCAA) metabolism. Research has demonstrated a positive association between circulating L‐valine concentrations and specific intestinal bacterial populations in NSCLC patients. As L‐valine is essential for optimal T cell activation, its deficiency impairs lymphocyte function by dysregulating mechanistic target of rapamycin complex 1 (mTORC1)‐dependent signaling cascades, while concurrently promoting metabolic reprogramming in tumor cells [31]. Tryptophan catabolites, including kynurenine and various indole compounds, mediate complex immunomodulatory effects primarily through AhR‐dependent mechanisms [56]. These microbial metabolites enhance intestinal barrier integrity and attenuate pro‐inflammatory signaling by upregulating interleukin‐22 (IL‐22) production while suppressing nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) activation [44, 57, 58, 59, 60, 61]. Notably, indole derivatives facilitate the differentiation of tumor‐associated macrophages (TAMs) into immunotolerant M2‐like macrophages, resulting in compromised CD8+ T cell activity and subsequent suppression of anti‐tumor immunity [62]. By increasing the levels of Bacillota, Clostridia and their metabolites, such as indole‐3‐carboxylic acid, it is possible to increase the levels of macrophage inflammatory protein‐3α in the circulation and reduce the number of α4β7+ regulatory T cells, thereby enhancing the efficacy of PD‐1 inhibitors [63]. Regarding bile acid (BA) metabolism, the immunomodulatory properties of BA include suppression of the NOD‐like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation through G protein‐coupled bile acid receptor 1 (TGR5)‐mediated signaling pathways, resulting in decreased interleukin‐1β (IL‐1β) production [64, 65]. Certain bile acid derivatives exhibit significant immunoregulatory properties. The metabolite 3‐oxocholic acid (3‐oxoCA) modulates T cell polarization by downregulating Retinoic Acid Receptor‐Related Orphan Receptor Gamma t (RORγt) activity, thereby inhibiting Th17 cell development while promoting regulatory T cell function [66, 67]. Through G protein‐coupled bile acid receptor 1 (TGR5)‐dependent mechanisms, ursodeoxycholic acid (UDCA) upregulates suppressor of cytokine signaling 1 (SOCS1) expression in macrophages, effectively suppressing lipopolysaccharide (LPS)‐induced NF‐κB and mitogen‐activated protein kinase (MAPK) activation and subsequent production of inflammatory mediators including IL‐1β, Interleukin‐6 (IL‐6), Interleukin‐12 (IL‐12), and tumor necrosis factor‐α (TNF‐α) [68]. Furthermore, Isolithocholic acid (iso‐LCA) negatively regulates natural killer (NK) cell activity via interference with cyclic AMP‐responsive element‐binding protein 1 (CREB1) phosphorylation [69]. Interactions of Gut‐Lung Immune Cells The core of gut‐lung immune cell interactions lies in the activation of immune cells by gut microbiota, releasing cytokines or chemokines that migrate to the lungs through metabolic circulation, reshaping the immune microenvironment. Cytokines released by pulmonary immune cells return to the gut through metabolism, affecting gut microbiota and the environment. This process depends on the metabolic axis. GALT and MALT regulate the immune microenvironment via reciprocal immune cell migration [44]. For instance, intestinal IL‐25 activates group 2 innate lymphoid cells (ILC2s), which migrate through the sphingosine‐1‐phosphate/sphingosine‐1‐phosphate receptor 4 (S1P/S1PR4) axis to pulmonary tissues, inducing eosinophil‐mediated inflammation [70]. These lung‐resident ILC2s exert anti‐tumor effects by secreting IL‐5/IL‐13 and engaging the inducible T‐cell costimulator/OX40 ligand (ICOS/OX40L) axis, synergizing with adaptive immune cells to suppress tumor progression and enhance immunotherapy responses [71, 72, 73]. Intestinal dendritic cells (DCs) migrate to the lungs after stimulation by microbiota, promoting IL‐12 secretion and enhancing Th1‐type anti‐tumor immunity [44, 74]. Certain microbial taxa (e.g., Prevotella) induce intestinal Th17 cell activation and subsequent pulmonary homing [75], where IL‐17A produced by Th17 cells can stimulate the secretion of β‐defensins by activating the Signal Transducer and Activator of Transcription 3 (STAT3) pathway within intestinal epithelial cells, selectively inhibiting the excessive proliferation of Proteobacteria [76]. SCFAs derived from gut microbiota reach the lungs via the bloodstream, facilitating the M2 polarization of alveolar macrophages and alleviating inflammatory responses triggered by Th17 cells, thereby reducing the immune pathological damage associated with lung cancer [77, 78, 79]. Conversely, pulmonary inflammation generates interferon‐γ (IFN‐γ) and TNF‐α that impair intestinal tight junctions [80, 81], while translocated LPS exacerbates dysbiosis through Toll‐like receptor 4 (TLR4) activation, completing this pathological feedback loop [82]. Related Signaling Pathways Phosphatidylinositol 3‐Kinase‐Protein Kinase B‐Mammalian Target of Rapamycin (PI3K‐Akt–mTOR) Signaling Pathway The PI3K‐Akt–mTOR signaling pathway is crucial for regulating cell growth and proliferation. The main pathway involves activated PI3K phosphorylating PIP2 to produce membrane‐associated PIP3, while phosphatase and tensin homolog (PTEN) acts as a negative regulator, catalyzing the dephosphorylation of PIP3 to PIP2. Subsequently, PIP3 recruits phosphoinositide‐dependent kinase 1 (PDK1) to the cell membrane, activating Akt, which then activates the mTORC1 complex and regulates downstream effectors such as S6K, 4E‐BP1, and p34 [83]. The PI3K‐Akt–mTOR signaling pathway influences the immune microenvironment in NSCLC by regulating T cell function, macrophage polarization, and autophagy. For instance, certain factors such as YY1 can induce M2 polarization of macrophages by activating the PI3K‐Akt–mTOR signaling pathway [84]. Additionally, exosomes containing miR‐155‐5p from M2 macrophages can activate the PI3K‐Akt–mTOR pathway, inducing epithelial‐mesenchymal transition (EMT) and tumor invasion. This process also weakens the cytotoxicity of CD8+ T cells, exacerbating immune evasion [85]. Moreover, the PI3K/Akt/mTOR pathway can regulate autophagy processes, affecting cell death mechanisms such as ferroptosis or necroptosis, further disrupting the balance of the immune microenvironment [86]. In NSCLC, tumor metabolic adaptation characterized by elevated glycolytic flux activates the PI3K‐Akt–mTOR signaling pathway. This pathway, via downstream regulators including 4E‐BP1, NF‐κB, STAT3, and c‐MYC, promotes post‐translational modification and stability of PD‐L1, leading to increased PD‐L1 expression and subsequent inhibition of T cell activation and anti‐tumor immunity [87]. Consequently, activation of this axis drives resistance to ICIs, particularly in PIK3CA‐mutant NSCLC, and clinically correlates with a diminished therapeutic response to PD‐1 blockade [88, 89]. Notably, modulation of gut microbiota composition can enhance immune checkpoint inhibitor responses via the PI3K‐Akt–mTOR pathway. For instance, the microbial metabolite sodium butyrate stimulates PI3K‐Akt‐dependent PD‐L1 expression in tumor cells. This butyrate‐mediated PD‐L1 upregulation converts “cold” tumors with intrinsically low PD‐L1 levels into more immunologically active tumors, thereby improving T cell‐mediated anti‐tumor immunity and providing a strong rationale for combining butyrate with PD‐1/PD‐L1 blockade. Furthermore, gut microbial communities orchestrate systemic immunometabolic effects via this same signaling cascade, such as glutamine metabolic reprogramming, which facilitates T cell priming and clonal expansion. These coordinated effects ultimately optimize cancer immunotherapy outcomes. These findings establish the PI3K‐Akt–mTOR pathway as a pivotal microbial‐immune interface, revealing novel therapeutic avenues for optimizing cancer immunotherapy outcomes [90, 91]. NLRP3 Signaling Pathway The NLRP3 inflammasome serves as a key molecular platform that recognizes both microbial components (PAMPs) and host‐derived danger signals (DAMPs), triggering inflammasome complex formation. Upon activation, NLRP3 recruits ASC and procaspase‐1, leading to caspase‐1‐dependent proteolytic processing of pro‐IL‐1β and pro‐IL‐18 into their bioactive forms. Concurrently, caspase‐1‐mediated cleavage of gasdermin D(GSDMD) generates plasma membrane pores that enable cytokine secretion and induce pyroptotic cell death [92]. A pivotal function of the NLRP3 signaling pathway is to establish an immune environment conducive to tumor proliferation and dissemination [93, 94]. In NSCLC, dysregulated NLRP3 activation promotes IL‐1β and IL‐18 release, creating an inflammatory milieu with context‐dependent immunostimulatory or immunosuppressive effects [95, 96, 97, 98]. The pathway demonstrates antitumor potential through pyroptosis‐induced dendritic cell activation and enhanced CD8+ T cell cross‐priming [99, 100]. However, excessive immune cell pyroptosis may paradoxically suppress antitumor immunity by impairing lymphocyte trafficking and cytokine production, ultimately fostering an immune‐evasive tumor microenvironment [98, 101, 102]. Moreover, the NLRP3 also exhibits dual roles in NSCLC immunotherapy. Clinical evidence reveals that elevated NLRP3 activity correlates with improved response to PD‐1 blockade, as inflammasome activation enhances macrophage phagocytic capacity while decreasing immunosuppressive M2 polarization and myeloid‐derived suppressor cells (MDSC) accumulation. These changes potentiate the therapeutic efficacy of PD‐1 inhibitors like pembrolizumab [103]. Paradoxically, separate studies demonstrate that the inhibition or reversal of NLRP3 inflammasome activity can overcome immunotherapy resistance by attenuating immunosuppressive mechanisms, thereby improving PD‐L1 inhibitor response rates and patient survival outcomes [104, 105]. This apparent contradiction may reflect the pathway's pleiotropic effects across different tumor microenvironments. Notably, NLRP3 functionally interacts with both MAPK and PI3K/Akt/mTOR cascades to regulate autophagic flux, collectively promoting tumor cell motility and metastatic potential [106, 107]. These cross‐pathway interactions underscore the complexity of targeting inflammasome signaling for cancer therapy. Gut microbiota and their bioactive metabolites exert bidirectional regulation of NLRP3 inflammasome activity, modulating IL‐1β and IL‐18 production to influence inflammatory responses. This microbial‐immunological crosstalk contributes to tumor microenvironment remodeling and may potentiate immunotherapy efficacy [108, 109, 110, 111]. For example, Akkermansia muciniphila (A. muciniphila ), as one of the core symbiotic bacteria in the gut, promotes M1‐like TAMs activation through NLRP3 activation and reshapes the tumor microenvironment through metabolic interactions with the intratumoral microbiota. Furthermore, synergistic administration of A. muciniphila with PD‐1 blockade demonstrates enhanced therapeutic efficacy through increased intratumoral CD8+ T lymphocyte accumulation, effectively reversing primary resistance to checkpoint inhibition [112]. T Cell Receptor (TCR) Signaling Pathway The TCR serves as a critical surface molecule enabling T lymphocytes to recognize tumor‐derived peptides presented by MHC molecules. Upon antigen engagement, the TCR‐CD3 complex recruits lymphocyte‐specific kinase (Lck), which phosphorylates immunoreceptor tyrosine‐based activation motifs (ITAMs). This phosphorylation event facilitates the binding and subsequent activation of Zeta‐chain‐associated protein kinase of 70 kDa (ZAP70), which then phosphorylates linker for activation of T cells (LAT). The phosphorylated LAT assembles a signaling complex containing downstream effectors such as phospholipase C gamma (PLC‐γ), ultimately leading to activator protein 1 (AP‐1) activation and subsequent T cell differentiation and proliferation [113]. Effective TCR signaling triggers CD8+ cytotoxic T lymphocytes to release effector molecules including interferon‐gamma (IFN‐γ) and tumor necrosis factor‐alpha (TNF‐α), along with cytotoxic granules containing perforin and granzyme B, collectively mediating tumor cell lysis [114, 115]. Nevertheless, the tumor microenvironment frequently impairs TCR‐mediated antitumor immunity through diverse immunosuppressive mechanisms. A predominant inhibitory pathway involves PD‐1/PD‐L1 axis‐mediated suppression of downstream TCR signaling components, including the PI3K‐AKT cascade, which attenuates CD8+ T cell activation and cytotoxic potential [115, 116]. Furthermore, tumor‐infiltrating regulatory T cells (Tregs) exacerbate this immunosuppression through IL‐10 and TGF‐β secretion, directly impairing TCR signal transduction in cytotoxic T lymphocytes and blunting antitumor responses [115, 117]. Clinical studies demonstrate that PD‐1/PD‐L1 blockade can effectively counteract these inhibitory mechanisms, restoring TCR signaling competence and enhancing CD8+ T cell proliferation, tumor infiltration, and cytotoxic activity [102]. Importantly, NSCLC patients exhibiting robust TCR co‐expression signatures demonstrate superior immunotherapy responses and significantly extended progression‐free survival, whereas those with weak TCR signaling characteristics are more prone to therapeutic resistance [118]. Emerging research demonstrates that gut microbial metabolites can potentiate antitumor immunity through well‐defined mechanistic cascades. Specifically, the SCFA sodium butyrate acts as an endogenous histone deacetylase (HDAC) inhibitor and epigenetically upregulates PD‐1 and CD28 expression in CD8+ T cells via histone 3 lysine 27 acetylation (H3K27ac) at gene promoter regions [119]. This epigenetic regulation enhances CD4+ T cell responses and activates peripheral blood mononuclear cells (PBMCs) through TCR‐mediated mechanisms, leading to induced apoptosis in lung cancer cells and suppressed tumor proliferation [120]. Another microbial metabolite, L‐selenomethionine (L‐SeMet), enhances TCR signal transduction by promoting Lck phosphorylation, which subsequently boosts CD8+ T cell effector functions and antitumor activity [121]. These findings highlight the therapeutic potential of targeting microbial‐TCR interactions for cancer immunotherapy. NF‐κB Signaling Pathway The NF‐κB signaling pathway is initiated through TLR4‐mediated recognition of specific ligands such as LPS, triggering a downstream cascade where TLR4 recruits Myeloid differentiation factor 88 (MyD88) to activate interleukin‐1 receptor‐associated kinase (IRAK) and transforming growth factor‐β‐activated kinase 1 (TAK1), leading to IKK complex phosphorylation. Activated κappa B kinase (IKK) then phosphorylates κappa B (IκB), resulting in NF‐κB nuclear translocation and subsequent transcriptional upregulation of pro‐inflammatory cytokines (e.g., IL‐6, TNF‐α) and chemokines that promote tumor‐associated inflammationt [122, 123, 124]. In NSCLC, this pathway critically shapes the immune microenvironment by regulating immune checkpoint expression, sustaining inflammatory responses, and driving macrophage polarization toward immunosuppressive phenotypes, collectively influencing anti‐tumor immunity [96, 125]. In immunotherapy, the NF‐κB signaling pathway also exhibits dual roles. NF‐κB upregulates key transcription factors such as Forkhead box P3 (Foxp3) in the Treg lineage by binding to immune suppressive gene promoters, inhibiting T cell anti‐tumor functions and activating PD‐L1 transcription, thereby mediating immune evasion and reducing the efficacy of immunotherapy [126, 127]. Conversely, NF‐κB activation can enhance antitumor immunity when appropriately modulated—TLR4 agonist monophosphoryl lipid A (MPLA) combined with transmembrane protein shisa family member 3 (SHISA3) reprograms immunosuppressive M2 TAMs into pro‐inflammatory M1 macrophages via NF‐κB signaling, thereby potentiating CD8+ T cell cytotoxicity and improving PD‐1 blockade efficacy [124]. Furthermore, gut microbiota can influence cytokine networks and immune response pathways through the NF‐κB signaling pathway, thereby remotely modulating the immune microenvironment and the effectiveness of NSCLC immunotherapy. For example, extracellular vesicles (EVs) derived from gut microbiota are internalized by lung cancer cells through a protein‐dependent endocytosis mechanism, leading to an upregulation of PD‐L1 expression in tumor cells via the NF‐κB signaling pathway. This interaction synergizes with anti‐PD‐1 treatment, resulting in an increased number of tumor‐infiltrating CD8+ T cells. Microbial‐derived EVs activate NF‐κB signaling to upregulate PD‐L1 on tumor cells, creating actionable targets for checkpoint blockade and ultimately enhancing CD8+ T lymphocyte infiltration, thereby improving the therapeutic response to immunotherapy [128, 129]. MAPK Signaling Pathway The MAPK pathway represents a conserved intracellular signaling cascade that comprises a three‐tiered kinase cascade, upstream rat sarcoma(Ras) protein activates rapidly accelerated fibrosarcoma (Raf) or apoptosis signal‐regulating kinase 1(ASK1) or TAK1, which subsequently phosphorylates mitogen‐activated protein kinase kinases (MEK) (e.g., MEK1/2, MEK4/7, MEK3/6), ultimately activating extracellular signal‐regulated kinases (ERK) (e.g., ERK1/2, JNK1/2, p38), leading to their entry into the nucleus to phosphorzylate transcription factors (e.g., cellular FBJ murine osteosarcoma viral oncogene homolog(c‐Fos), activating transcription factor 2(ATF2), cellular myelocytomatosis viral oncogene homolog(c‐Myc), etc.) and initiate downstream gene regulation of cell proliferation, survival, and differentiation [130]. Among the different subfamilies of MAPK, ERK1/2 promotes cell differentiation, division, and inhibits apoptosis, while p38 MAPK and JNK1/2 induce apoptosis [131, 132]. In NSCLC, approximately 30% of cases harbor mutations in oncogenes, notably the Kirsten rat sarcoma viral oncogene homolog (KRAS) and the epidermal growth factor receptor (EGFR), promoting tumor progression through sustained activation of the MAPK pathway [115, 131]. The specific mechanism involves activated MAPK signaling recruiting Tregs to form an immunosuppressive microenvironment and upregulating genes related to macrophage polarization (e.g., colony‐stimulating factor 1(CSF1), C‐C motif chemokine ligand 2(CCL2)), promoting the infiltration of TAMs into the tumor microenvironment and accelerating NSCLC progression [115, 133]. Within the context of immunotherapy, MAPK signaling contributes to immune evasion by transcriptionally upregulating PD‐L1 expression in lung cancer cells through activation of transcription factors such as brachyury. This elevated PD‐L1 engages with PD‐1 receptors on T lymphocytes, impairing CD8+ T cell recruitment and effector functions, ultimately establishing an immunosuppressive tumor microenvironment [134]. Consequently, pharmacological inhibition of MAPK signaling components (e.g., MEK or ERK inhibitors) may reverse these immunosuppressive effects and synergize with PD‐1/PD‐L1 blockade strategies [135]. Clinical evidence supports this approach, demonstrating improved therapeutic outcomes when combining MEK inhibitors like trametinib with ICIs [136, 137]. Certain gut fungi promote tumor proliferation, invasion, and migration in NSCLC by downregulating the expression of Caspase Recruitment Domain‐Containing Protein 9 (CARD9), thereby activating the MAPK‐p38 signaling pathway [138]. Furthermore, metabolites of Gram‐negative bacteria, such as LPS, have been shown to stimulate CCR1 expression and upregulate PD‐L1 levels through MAPK phosphorylation, consequently inducing malignant tumor progression and reducing the efficacy of immunotherapy [139]. Therefore, targeting gut microbiota may reverse immune suppression through the MAPK pathway, improving the efficacy of immunotherapy (Figure 2). Key signaling pathways of gut microbiota affecting NSCLC immunotherapy. This diagram shows key pathways: (1) Activation of PI3K‐AKT–mTOR signaling pathway by sodium butyrate affecting ICIs. (2) NLRP3 signaling pathway activates caspase‐1, producing IL‐1β and IL‐18, and A. muciniphila promotes M1 macrophage polarization, impacting immune responses through the NLRP3 signaling pathway. (3) TCR signaling activates T cells through LAT and PLCγ, with butyrate enhancing PD‐1 and CD28 expression. (4) NF‐κB signaling pathway responds to LPS, activating NF‐κB to regulate IL‐6 and IL‐10 expression. (5) The MAPK pathway has three branches: ERK, JNK, and p38, regulating cell functions via cascade phosphorylation and is activated by LPS, increasing PD‐L1 levels that impact immune therapy. Clinical Applications Targeting Gut Microbiota to Improve Immunotherapy Efficacy Regulating specific microbiota might affect how well immunotherapy works. Studies have shown that a microbiota structure rich in Actinobacteria, Bacteroides, and Verrucomicrobia correlates positively with the success of immunotherapy, while the amount of Bacillota might be linked to fewer immune‐related side effects [140]. The abundance of certain specific microbiota (e.g., Faecalibacterium) in the intestines of immunotherapy responders significantly increases, accompanied by elevated levels of SCFAs, particularly butyrate, acetate, and caproate. Therefore, therapeutic strategies including FMT, probiotic/prebiotic supplementation, and nutritional interventions can modulate immunotherapy efficacy through restoration of microbial community diversity, selective enrichment of beneficial bacterial taxa, and alteration of microbiota‐derived bioactive metabolites [141]. These microbiota‐targeted approaches demonstrate significant potential for enhancing checkpoint inhibitor responsiveness by systemically reshaping host immunity. Application of FMT Animal studies have shown that FMT from immunotherapy responders, enriched with Faecalibacterium and Ruminococcus, can reduce Ki‐67 expression in murine models without affecting PD‐L1 levels, which cooperatively strengthens PD‐1‐targeted immunotherapy [141]. Furthermore, FMT from MS‐20‐treated donor mice to recipient mice can enhance the efficacy of anti‐PD‐1 therapy by promoting the accumulation of CD8+ T cells within tumors [142]. FMT from immunotherapy non‐responders treated with ginseng polysaccharides (GPs) delayed tumor growth in mice and increased the ratio of CD8+/CD4+ T cells in their blood and tumors; simultaneously, the gut microbiota profiles of the transplanted mice were found to resemble those of immunotherapy responders. This suggests that FMT‐mediated microbiota reconstruction may overcome resistance to immunosuppressive treatments through ecological reprogramming of the gut microbiome [55]. Animal studies revealed that antibiotic‐disrupted microbiota in tumor‐bearing mice could be effectively reconstituted through FMT from NSCLC patients demonstrating positive responses to combined chemo‐immunotherapy [143]. Clinical trials have also further confirmed the efficacy of FMT. Data from a clinical trial evaluating the efficacy and safety of FMT in combination with ICIs in patients with NSCLC and melanoma (NCT04951583) revealed an ORR of 80% in the NSCLC cohort (n = 20), with no grade ≥ 3 adverse events (AEs) observed [144]. In another single‐arm exploratory study of FMT combined with ICI in patients with advanced NSCLC, the median PFS was 1.5 months and the median OS was 12.1 months across seven patients; one patient achieved a partial response (PR) and one achieved stable disease (SD). However, clinical trial data on FMT are limited, and there is a lack of long‐term follow‐up data from multicentre, large‐scale trials [145]. A clinical trial for advanced NSCLC (NCT06403111) is currently evaluating the efficacy of FMT combined with chemotherapy and teriprizumab, aiming to improve the imbalance of the immune microenvironment and resistance issues by regulating the microbiota [146]. Pertaining to the safety profile of FMT, clinical investigations have demonstrated that FMT is a safe procedure for patients with melanoma and NSCLC, demonstrating adjuvant potential for checkpoint blockade therapy [147, 148]. Prospective randomized controlled trials will be essential to confirm therapeutic efficacy and establish evidence‐based treatment protocols. Furthermore, in the context of combined immunotherapy for lung cancer, FMT demonstrates superior potential over probiotics in terms of standardization and efficacy. Data from Phase I clinical trials of FMT are already available (with objective response rates of 20%–65% observed in melanoma in particular, which may serve as a reference for NSCLC). FMT restores gut microbial diversity and beneficial populations, with low serious adverse event rates under stringent donor screening. Regulatorily, FMT is classified as a medicinal product or advanced therapy, mandating GMP compliance. Conversely, probiotic efficacy evidence derives mainly from retrospective or single‐arm studies; their single or limited strains fail to replicate microbiota complexity and pose bacteremia risks in immunocompromised patients. Moreover, probiotics as food supplements face lax regulation and poor product consistency. Thus, in NSCLC immunotherapy, FMT surpasses probiotics in evidence level, mechanistic comprehensiveness, safety control, and regulatory standardization [149, 150, 151, 152, 153]. Application of Probiotics/Prebiotics and Antibiotics Accumulating evidence from multiple investigations demonstrates that probiotic administration may potentiate immune checkpoint inhibitor efficacy through several interconnected mechanisms such as reestablishment of intestinal microbial homeostasis, activation and maturation of dendritic cells, enhancement of cytotoxic T lymphocyte effector functions, and suppression of regulatory T cell activity, collectively contributing to attenuation of tumor‐mediated immunosuppression [154, 155, 156]. Animal studies have shown that prebiotic compounds, such as lychee proanthocyanidins, exert immunostimulatory effects by selectively enriching beneficial microbial taxa such as Lachnospiraceae UCG‐006 and Ruminococcus in the mouse gut, while simultaneously increasing production of immunomodulatory SCFAs including acetate, propionate, and butyrate. These microbial metabolites demonstrate significant capacity to suppress pulmonary metastasis in mouse models of colorectal cancer while synergistically enhancing immunotherapy response [157]. Clinical trials have further confirmed the efficacy of probiotics. A retrospective clinical study evaluating 294 patients with advanced NSCLC showed that, compared with the control group, probiotic users demonstrated a statistically significant improvement in PFS (8.5 months vs. 5.2 months), as well as higher disease control rate(DCR) (78.4% vs. 62.7%) and ORR (32.5% vs. 21.3%) [158]. Of particular clinical significance, the study demonstrated that the butyrate‐producing probiotic strain CBM588 significantly improved OS and PFS in patients with NSCLC (NCT06399419) receiving combination chemotherapy and immunotherapy. A full‐cohort analysis based on follow‐up data showed that the median overall survival (MST) had not yet been reached in the CBM588 group, compared with 13 months in the control group. Regarding PFS, the CBM588 group was 9 months, compared with 4.5 months in the control group. Furthermore, this difference was more pronounced in the PD‐L1 low‐expression subgroup, which is likely mediated by gut microbiota‐dependent immune regulation [159]. The therapeutic efficacy of probiotics exhibits notable dependence on treatment modality: while immunotherapy monotherapy demonstrates probiotic‐associated improvements in both PFS and OS, combined chemo‐immunotherapy primarily shows OS benefits. This differential effect likely reflects chemotherapy‐induced alterations in gut microbial ecology, highlighting the need for treatment‐specific microbiota modulation approaches [160, 161]. Importantly, probiotic formulations containing Lactobacillus and Bifidobacterium species can effectively abrogate the negative impacts of antibiotic exposure on immunotherapy outcomes, normalizing survival metrics in antibiotic‐treated NSCLC patients to levels comparable with antibiotic‐naïve cohorts [162]. Not all antibiotics negatively affect NSCLC treatment. In one clinical study, vancomycin combined with stereotactic body radiotherapy (SBRT) significantly improved PFS and OS compared to controls. Treatment altered patients' gut microbiota and metabolome, including reduced SCFAs and changes in key immunomodulatory metabolites. These shifts were linked to dendritic cell and T cell activation, indicating enhanced systemic immunity [163]. These findings support further research into microbiota‐targeted strategies as adjuvants to immunogenic therapies like radiotherapy or chemotherapy. Despite these promising findings, current probiotic research faces several methodological challenges including lack of standardized strain selection criteria, variable dosing protocols, and inconsistent timing of administration relative to immunotherapy. Future research efforts should prioritize well‐designed prospective randomized controlled trials to establish evidence‐based, personalized microbial intervention strategies [154, 162, 164, 165]. Dietary Interventions Emerging evidence suggests that specific dietary interventions may potentiate immunotherapy outcomes through microbiota‐mediated mechanisms. Nutritional regimens rich in fiber, polyphenols, and ω‐3 polyunsaturated fatty acids (e.g., the Mediterranean diet) promote the expansion of immunomodulatory gut microbes including Akkermansia and Bifidobacterium species, potentially enhancing immune checkpoint inhibitor (ICI) responses [166]. While dedicated clinical trials in NSCLC populations remain limited, such dietary patterns have demonstrated improved ICI efficacy in melanoma and colorectal cancer patients [167, 168]. Animal experiments reveal that polyphenol supplementation modulates bile acid‐taurine metabolic pathways via selective enrichment of Ruminococcaceae and Alistipes, resulting in restored CD8+ T cell tumor infiltration and reversal of PD‐1 inhibitor resistance in murine models [169]. The microbial fermentation of dietary fiber yields SCFAs that potentiate PD‐1/PD‐L1 blockade efficacy through TLR pathway activation, correlating with elevated objective response rates (ORR) in high‐fiber diet consumers [170, 171]. Notably, tryptophan‐restricted diets reduce aryl hydrocarbon receptor (AhR) signaling in TAMs, promoting intratumoral accumulation of TNF‐α+, IFN‐γ+, and CD8+ T lymphocytes [56, 172]. Furthermore, ketogenic dietary patterns enhance PD‐1 inhibitor activity through β‐hydroxybutyrate‐mediated microbiota modulation [173]. Potential as Biomarkers The human gut microbiota includes Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia, with Firmicutes and Bacteroidetes being dominant [174]. The F/B ratio serves as a significant indicator of gut microbiota imbalance, closely related to host metabolic health, immune regulation, and disease risk [175, 176]. In the development and treatment of NSCLC, differences in certain specific genera within microbiota imbalance can serve as biomarkers to predict patient survival prognosis, immunotherapy efficacy, and metastatic indicators. Firmicutes includes Clostridia (etc.) and Bacilli (Lactobacillaceae and Acidaminococcaceae, etc.), which are involved in glycolytic metabolism and the production of SCFAs. The overall abundance of Clostincluding Ruminococcaceae, Lachnospiraceae, Eubacteriaceae, and Veillonellaceaeridia is higher in immunotherapy responders, with the overall abundance of Ruminococcaceae associated with prolonged survival [177], and Faecalibacterium, particularly Faecalibacterium prausnitzii , correlating with immunotherapy response [178, 179]. Among Lachnospiraceae, Anaerostipes, Blautia, and Coprococcus, particularly Coprococcus comes , are associated with good immunotherapy responses [178, 179, 180]. In Eubacteriaceae, Hungatella and its species Hungatella hathewayi are enriched in non‐responders to immunotherapy [179, 181]. Notably, Butyricicoccus from Lachnospiraceae and Fusicatenibacter from Eubacteriaceae are associated with reduced irAEs and prolonged OS [182]. In Veillonellaceae, Phascolarctobacterium [183] is enriched in patients benefiting from immunotherapy and is associated with prolonged PFS, while the elevated levels of Veillonella [184] and Dialister [183] correlate with unfavorable clinical outcomes, including accelerated disease advancement, reduced PFS, and diminished OS. In Acidaminococcaceae, Monoglobus is also associated with good immunotherapy responses [181]. In Lactobacillaceae, Lactobacillus is related to immunotherapy response [185]. Bacteroidetes includes Bacteroides, Parabacteroides, and Prevotella, which are associated with high‐fiber diets. Among Bacteroides, Bacteroides vulgatus is significantly elevated in immunotherapy responders [55]. Parabacteroides is associated with longer PFS, and Parabacteroides distasonis correlates with immunotherapy response [55]. Higher abundance of Prevotellaceae NK3B31 is associated with increased mortality risk after immunotherapy combined with chemotherapy [182]. In the brain metastatic stage of NSCLC, levels of Fusobacteria increase, and Fusobacteria are enriched in low responders to immunotherapy [178, 186]. Rikenellaceae and its genus Alistipes are associated with good immunotherapy responses [177, 178]. However, Fournierella from Rikenellaceae is enriched in patients with brain metastases from NSCLC and may serve as a biomarker for predicting tumor metastasis [180]. During the brain metastatic phase of NSCLC, significant alterations in gut microbial composition are observed, characterized by an expansion of Proteobacteria and depletion of Actinobacteria [186]. Notably, increased Betaproteobacteria abundance correlates with irAEs development [181], while specific Actinobacteria subgroups demonstrate divergent clinical associations: Bifidobacteriaceae shows positive correlation with therapeutic response [178, 185], whereas Rothia is linked to reduced PFS and OS [177]. Within the Verrucomicrobia phylum, Akkermansia abundance is positively associated with survival outcomes [177]. These collective findings position the gut microbiome as a potential predictive biomarker for immunotherapy efficacy in NSCLC, with distinct microbial signatures exhibiting either favorable or unfavorable prognostic value for treatment response and patient survival (Table 2). TABLE 2Gut microbiota in immunotherapy.ApplianceCategorizationRole/bacteriaSignificanceBibliographyFMTTransplantation of fecal bacteria from immune responders (enriched for Faecalibacterium, Ruminococcus)Restoration of gut microbiota diversity reduces Ki‐67 expression without affecting PD‐L1 expressionInhibition of tumor progression[141]Transplantation of MS‐20 treated fecal bacteriaEnhanced CD8+ T cell infiltrationElevated anti‐PD‐1 efficacy and reduced tumor size in mouse models[142]FMT combined with ginseng polysaccharidesModulation of the tryptophan/kynurenine ratio reduces immunosuppressive metabolites and restructures the gut microbiotaReversing PD‐1 resistance in mouse models[55]FMT from responders to chemotherapy combined with immune checkpoint inhibitorsRestoration of microbial homeostasis enhances effector T cell infiltration and activation while modulating cytokine profilesEnhancing the efficacy of ICIs[143]FMT combined with tislelizumab and chemotherapy (NCT06403111)Modulation of gut microbiota improves the immune microenvironment and enhances the synergistic effects of chemoimmunotherapyThe anticipated 12‐month PFS rate was 55%[146]ProbioticsProbiotics ( Clostridium butyricum /Bifidobacterium/Antibiotic‐resistant lactic acid bacteria)Regulation of flora diversity and enhancement of CD8+ T‐cell functionProlonged PFS in NSCLC patients[158]Probiotic with Clostridium butyricum (CBM588)Produces butyric acid, which enhances the anti‐tumor response of CD8+ T cellsSignificant prolongation of OS in patients with low PD‐L1 expression[159]Probiotics (Lactobacillus/Bifidobacterium/Clostridium butyricum etc.)Reverses the effects of antibiotics and restores flora balanceIncreased response rate to NSCLC immunotherapy, counteracted OS deterioration due to antibiotic use, and improved DCR, ORR, and PFS[162]PrebioticsLychee ProanthocyanidinsTriggering of the gut‐lung axis and modulation of gut flora metabolites (SCFAs) increases CD8+ cytotoxic T‐lymphocyte infiltration and decreases macrophage numbersInhibition of colon cancer lung metastasis as an adjuvant drug for immunotherapy[157]Dietary interventionsMediterranean dietPromotion of Akkermansia/Bifidobacterium proliferationImproving PD‐L1 Inhibitor Efficacy[166, 167, 168]High‐fiber dietDietary fiber metabolism generates SCFAs to activate the TLR pathwayImproving ORR in patients receiving PD‐1/PD‐L1 inhibitors[170, 171]Polyphenolic foods (e.g., berries)Upregulation of bile acid‐taurine metabolism restores CD8+T cell infiltrationReversal of resistance to PD‐1 inhibitors in mice[169]Low tryptophan dietInhibition of the AhR pathway increases TNFα+IFNγ+ CD8+ T cellsInhibition of tryptophan (e.g., IDO1) improves immunosuppressant efficacy[56, 172]Ketogenic dietActivation of immunity by beta‐hydroxybutyrate‐colony axisEnhanced anti‐PD‐1 effect[173]Immunotherapy‐related biomarkersPrognostic biomarkers Ruminococcaceae, Butyricicoccus, Fusicatenibacter, Phascolarctobacterium, Parabacteroides, Akkermansia Associated with prolonged survival[177, 182, 183, 184] Veillonella, Dialister, Prevotellaceae NK3B31, Rothia Associated with shorter survival[177, 182, 183, 184]Efficacy biomarkers Clostridia, Faecalibacterium, Faecalibacterium prausnitzii, Anaerostipes, g_Blautia, Coprococcus comes, Monoglobus, Lactobacillaceae, Bacteroides vulgatus, Parabacteroides distasonis, Rikenellaceae, Alistipes, Bifidobacteriaceae Associated with immunotherapy response[141, 178, 180, 182, 186] Hungatella, Hungatella hathewayi, Fusobacteria Associated with no response to immunotherapy[178, 179, 180, 181, 186] Butyricicoccus, Fusicatenibacter, Betaproteobacteria Associated with irAEs[181, 182]Fransfer biomarkers Fusobacteria, Fournierella, Proteobacteria Associated with increased risk of brain metastases[178, 180, 186] Gut microbiota in immunotherapy. Conclusion ICIs are powerful therapeutic agents for NSCLC, but not all patients achieve a satisfactory response. Modulating the gut microbiota may represent a novel strategy to make ICIs work better [2]. Gut microbiota regulates the response to NSCLC immunotherapy through the immune‐gut microbiota‐metabolism axis, including specific microbiota and metabolic products that influence immune cell activation, cytokine release, and other factors affecting the immune microenvironment, thereby improving or diminishing the efficacy of immunotherapy [37, 38]. This immunomodulatory mechanism is mediated through coordinated metabolic pathway activity and immune cell trafficking, involving precise modulation of immunometabolic axes and targeted recruitment of immune effector cells to tumor sites [39, 40]. Adjusting the diversity of gut microbiota through FMT [141, 142], probiotic supplementation [154, 155, 156], and dietary interventions [170, 171] is expected to improve the efficacy of immunotherapy, especially for those who do not respond to immunotherapy. At the same time, the characteristic microbiota and metabolic products in NSCLC patients undergoing immunotherapy can serve as biomarkers to predict tumor prognosis, metastasis, and immunotherapy efficacy [177, 184, 185]. Therefore, targeting gut microbiota to improve NSCLC immunotherapy is a powerful strategy worth further exploration and experimentation. However, this strategy has many limitations. First, the interaction mechanisms between microbiota and immunity are complex, and how microbial metabolites precisely regulate the tumor microenvironment is still unclear. Individual genetic backgrounds, diet, antibiotic use, and other confounding factors may obscure the true effects of microbiota [187, 188, 189]. Most studies have not systematically controlled for key variables such as the frequency, timing, type, indications, dosage, class, and baseline risk of antibiotic use. Consequently, when analyzing how the gut microbiota influences the efficacy of ICIs, it is equally necessary to accurately record dietary components (such as fiber and fat) and the duration, type, and dosage of antibiotic exposure, and to employ statistical methods such as multivariate regression or instrumental variable analysis to isolate independent effects. Without such quantification, it will be impossible to distinguish whether changes in the microbiome stem from the intervention itself or from confounding factors, thereby undermining the reliability of the conclusions [190]. Second, existing clinical trials have small sample sizes, and there is a lack of uniform standards for microbiota intervention methods, clinical trial efficacy assessment, sample collection methods, and sequencing platforms. Additionally, clinical trials may pose safety risks, for example, FMT may transmit multidrug‐resistant bacteria or pathogenic microorganisms carried by the donor, leading to infection or excessive immune activation (such as colitis), whilst probiotics may trigger bacteraemia or opportunistic infections in immunocompromised patients, such as those with severe neutropenia or impaired mucosal barriers [191, 192]. To address these risks, standardized management is essential. Rigorous donor screening is key to reducing the risk of transmission associated with FMT—this includes testing donors for multidrug‐resistant bacteria, intestinal pathogens, and viruses to ensure the safety of microbiome products. Secondly, it is crucial to establish an adverse event monitoring and reporting system to systematically collect and report complications arising from microbiome interventions (such as post‐FMT infections and probiotic‐associated bacteraemia), thereby providing a basis for clinical decision‐making [193, 194, 195]. Finally, microbiota preparations (e.g., FMT) have yet to receive approval from the FDA/NMPA for cancer treatment and lack definitive ethical and quality control standards [196]. Key ethical challenges in gut microbiota research include sample ownership, privacy protection, and informed consent. Fecal samples and resulting microbiome data raise unresolved questions regarding ownership—whether it lies with donors or institutions. As microbiome data are highly personally identifiable, effective anonymization is required to prevent re‐identification during sharing or reuse. Given the established links between gut microbiota and various diseases, future use of such data may reveal participants' latent health risks, underscoring the need for explicit informed consent. Failure to address these issues may lead to ethical concerns and hinder clinical translation [197, 198, 199]. To ensure standardized fecal microbiota transplantation (FMT), it is recommended to collect baseline and post‐treatment samples at multiple time points, store all fecal samples at −80°C with cryoprotectants, prioritize metagenomic sequencing for strain‐level resolution, and apply standardized bioinformatics tools to assess microbiota engraftment. Donor selection must follow strict infectious disease screening criteria. The bacterial suspension should be prepared under anaerobic conditions with double centrifugation. The administration route—endoscopic infusion, enema, or oral lyophilized capsules—can be chosen based on disease type and patient needs, thereby ensuring comparability and reproducibility throughout the procedure [200, 201, 202, 203]. Future research should utilize cutting‐edge technological platforms to address these knowledge gaps, including multi‐omics integration, single‐cell technologies and artificial intelligence (AI)‐driven models, in order to systematically elucidate microbiota‐immune interactions in tumor biology and decipher the complex interactions between the gut microbiota and anti‐tumor immunity in NSCLC [204, 205]. In clinical practice, cross‐center sequencing and omics platforms should be established to standardize the collection, storage, and data processing of biospecimens (e.g., feces and tumor tissues). Clear ethical guidelines are required, alongside rigorously designed phase III randomized controlled trials (RCTs), quality control standards for microbiota preparations, and standardized analytical methods. The gut microbiota represents a key intervenable and monitorable factor in NSCLC immunotherapy; however, its clinical translation hinges on standardized analyses and high‐quality RCTs. Future efforts should combine microbiomics, immunology, and clinical oncology to bridge the gap from “correlation” to “causation.” Author Contributions Liming Zhu: investigation, project administration, writing – original draft. Xiangyu Zhang: writing – original draft. Dong Niu: writing – original draft. Jiayao Xu: project administration, writing – original draft. Chunhui Jin: investigation, project administration, writing – review and editing. Funding The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Traditional Chinese Medicine Technology Development Plan of Jiangsu Provincial Administration of Traditional Chinese Medicine (ZD202324), the Science and Technology Plan Project of Traditional Chinese Medicine Hospitals from Wuxi Municipal Administration of Traditional Chinese Medicine (ZYYB23), and the Natural Science Foundation of Nanjing University of Chinese Medicine (XZR2023024). Ethics Statement The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.